104195-61-1 Usage
Description
Rubitecan, also known as 10-Nitrocamptothecin, is a derivative of Camptothecin (C175150) with potent anticancer properties. It is characterized by its ability to inhibit the activity of topoisomerase I, a crucial enzyme involved in DNA replication. This inhibition leads to the prevention of cancer cell proliferation and the induction of cell death, making Rubitecan a promising candidate for cancer treatment.
Uses
Used in Anticancer Applications:
Rubitecan is used as an anticancer agent for the treatment of various types of cancer, including solid tumors and hyperproliferative diseases. Its mechanism of action involves the inhibition of topoisomerase I, which disrupts DNA replication and ultimately leads to the death of cancer cells. This makes Rubitecan a valuable addition to the arsenal of cancer-fighting drugs.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of Rubitecan, researchers have developed various drug delivery systems. These systems aim to improve the drug's solubility, stability, and targeted delivery to cancer cells, thereby increasing its therapeutic potential and reducing potential side effects. Organic and metallic nanoparticles, as well as other advanced drug delivery technologies, are being explored to optimize Rubitecan's performance in cancer treatment.
Check Digit Verification of cas no
The CAS Registry Mumber 104195-61-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,1,9 and 5 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 104195-61:
(8*1)+(7*0)+(6*4)+(5*1)+(4*9)+(3*5)+(2*6)+(1*1)=101
101 % 10 = 1
So 104195-61-1 is a valid CAS Registry Number.
InChI:InChI=1/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1
104195-61-1Relevant articles and documents
Plant Antitumor Agents. 30. Synthesis and Structure Activity of Novel Camptothecin Analogs
Wall, Monroe E.,Wani, Mansukh C.,Nicholas, Allan W.,Manikumar, Govindarajan,Tele, Chhagan,et al.
, p. 2689 - 2700 (2007/10/02)
A large number of camptothecin (CPT) analogs have been prepared in the 20S, 20RS, and 20R configurations with a number of ring A substituents.Topoisomerase I (T-I) inhibition data (IC50) have been obtained by standard procedures.In general, substitution at the 9 or 10 positions with amino, halogeno, or hydroxyl groups in compounds with 20S configuration results in compounds with enhanced T-1 inhibition.Compounds in the 20RS configuration were less active in vitro and in vivo and those in the 20R configuration were inactive.Compounds with 10,11-methylenedioxy substitution on ring A displayed a marked increase in potency in the T-I inhibition assay.The activities of some of the analogs as determined in a variety of in vivo assays including the L-1210 mouse leukemia assay were, in general, in accord with T-I inhibition.A number of water-soluble analogs such as 20-glycinate esters, 9-glycinamides, or hydrolyzed lactone salts were prepared and tested in in vitro and in vivo assays.In general, these compounds were less active than CPT both in terms of T-I inhibition and life prolongation in the L-1210 assay.However, certain 20-glycinate esters showed good in vivo activity after iv administration.
